January 31, 2017
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa
Paris, France, 31 January 2017 – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and diseases of the central nervous system, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
Please find the full PDF press release attached.
| GenSight Biologics
Thomas Gidoin Chief Financial Officer +33 (0)1 76 21 72 20 |
NewCap
Investor Relations Florent Alba +33 (0)1 44 71 98 55 |
Rooney Partners
Media Relations Marion Janic +1-212-223-4017 |
Source: Gensight
